Eric L. Dobmeier

Biography

Eric oversees the company's business development, corporate communications, investor relations, manufacturing and program/alliance management groups, as well as corporate strategy and operational initiatives. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Takeda Pharmaceutical Company for ADCETRIS, the global co-development and co-commercialization agreement for enfortumab vedotin with Astellas Pharma and multiple ADC collaborations with leading biotechnology and pharmaceutical companies. He has also been directly involved in raising more than $1.2 billion in equity capital for Seattle Genetics.

Research Interest

Biotechnology and Pharmaceutical companies